the aid library

LIST OPTIONS

Filter

4388

Management & Post-Exposure Prophylaxis of Potential HIV and Hepatitis B Exposure in Children, Adolescents & Adults Guidelines (South Africa)

Western Cape Government Health, South Africa (2019) C1

1PEP GUIDELINES | 2019 EDITION. The prevalence of both HIV and Hepatitis B is high in South Africa therefore there is a significant risk of acquiring these infections following exposure to infected material. Studies suggest that post- exposure prophylaxis (PEP) with highly active antiretroviral trea... more

External Link

Shorter Treatment for Nonsevere Tuberculosis in African and Indian Children
recommended

Turkova, A.; G.H. Wills, E. Wobudeya, et al. (2022) C2

N Engl J Med 2022; 386:911-922, DOI: 10.1056/NEJMoa2104535 Four months of antituberculosis treatment was noninferior to 6 months of treatment in children with drug-susceptible, nonsevere, smear-negative tuberculosis (SHINE Study)

Download (149)

View PDF (201)

WHO interim guidelines for the treatment of gambiense human African trypanosomiasis

World Health Organization WHO (2019) C_WHO

This document focuses on the management of patients affected by gambiense HAT and constitutes an update to the WHO therapeutic guidance issued in 2013. The main changes in recommendations concern the criteria and methods for deciding the treatment among the new set of therapeutic options and the pa... more

Download (118)

View PDF (136)

The role of HIV viral suppression in improving individual health and reducing transmission

World Health Organisation (WHO) (2023) C_WHO

This policy brief describes key HIV viral load thresholds and the available viral load testing approaches for monitoring how well antiretroviral therapy is working for people living with HIV. It provides clarification for and elaborates upon the current treatment monitoring algorithm from the Consol... more

Download (285)

View PDF (384)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Worldwide rates of diagnosis and effective treatment for cystic fibrosis

Guo, J.; Garratt, A.; Hill, A. Journal of Cystic Fibrosis (2022) CC

Time has seen management for Cystic Fibrosis (CF) advance drastically, most recently in the development of the disease-modifying triple combination therapy ivacaftor/tezacaftor/elexacaftor. There is currently limited evidence regarding both the global epidemiology of CF and access to this transforma... more

Ongoing Living Update of Potential COVID-19 Therapeutics: Summary of Rapid Systematic Reviews. Rapid Review

Pan American Health Organisation PAHO (2020) C_WHO

As of 31 October 2020 This is the tenth edition of this summary of rapid systematic reviews, which includes the results of a rapid systematic review of currently available literature. More than 200 therapeutic options or their combinations are being investigated in more than 1,700 clinical trials. I... more

External Link

Optimal timing of HIV home‐based counselling and testing rounds in Western Kenya

Olney, Jack J.; Eaton, Jeffrey W.; Braitstein, Paula et al. (2018) CC

Journal of the International AIDS Society, vol. 21 Issue no. 6 e 25142
Weaknesses in care programmes providing anti‐retroviral therapy (ART) persist and are often instigated by late HIV diagnosis and poor linkage to care. We investigated the potential for a home‐based counselling and testin... more

Download (167)

View PDF (204)

Treatment of Leprosy

Lockwod DN. The International Textbook of Leprosy (2018) CC

This chapter discusses the antibacterial treatment of leprosy infections. Antibiotic treatment is a key component of leprosy treatment, as it is vital to prevent the progression of the infection. Treatment with rifampin and other antibiotics is highly effective and cures 98% of patients with the ... more

External Link

Global programme to eliminate lymphatic filariasis: progress report, 2020 - Weekly Epidemiological Record, 2021, vol. 96, 41 [‎full issue]‎

World Health Organization WHO; Institutional research information sharing iris (2021) C_WHO

Lymphatic filariasis (LF) is an avoidable, debilitating, disfiguring disease caused by infection with the filarial parasites Wuchereria bancrofti, Brugia malayi and B. timori. Globally, 51.4 million people are estimated to be infected. Lymphoedema and hydrocoele are the visible, chronic clinical co... more

Tuberculosis Infection Control in the Era of Expanding HIV Care and Treatment: Addendum to WHO Guidelines for the Prevention of Tuberculosis in Health Care Facilities in Resource-limited Settings

Center for Disease Control and Prevention, World Health Organisation (2007)

The goal of this addendum is to help management and staff  minimize the risk of TB transmission at facilities in resource limited settings in which a.) HIV-infected persons receive diagnosis, care, treatment,  and/or support, and b.) there is a high prevalence of HIV infection, both known  and... more

Download (700)

View PDF (1988)

HIV and Ebola Update

UNAIDS (2014)

It is essential that all people, including people living with HIV, are able to access health services and ongoing treatment. If people living with HIV who are on ART stop abruptly because they cannot access new supplies they could rapidly become unwell, drug resistance may build and the chances of o... more

Download (801)

View PDF (1427)

Guidance on temporary malaria control measures in Ebola-affected countries

World Health Organization (2014)

Malaria is a prevalent cause of febrile illnesses in areas with high transmission, and its clinical presentation overlaps with initial signs of Ebola disease. For this reason, the effectiveness of the Ebola response in Guinea, Liberia and Sierra Leone can be optimized through the deployment of targe... more

Download (261)

View PDF (490)

TB/HIV integration

AIDS and Rights Alliance for Southern Africa (2017) C2

TB heroes Hello, my name is Nurse X My job is to promote integrated HIV and TB prevention, care, treatment and support. This ensures that we, and my team of health care service providers treat everyone who is living with HIV and TB to have all the antiretroviral therapy (ART) and HIV care services... more

Download (1921)

View PDF (1351)

Selection and Use of Essential Medicines 2021
recommended

World Health Organization WHO (2021) C_WHO

The 23rd meeting of the WHO Expert Committee on Selection and Use of Essential Medicines was coordinated from Geneva, Switzerland, and held virtually from 21 June to 2 July 2021. The Committee considered 88 applications proposing additions, changes and deletions of medicines, medicine classes and fo... more

Download (948)

View PDF (2689)

Fever Diagnostic Technology Landscape
recommended

UNITAID World Health Organisation (WHO) (2018) C_WHO

1st edition. Unitaid’s report describes a slate of new devices that can more efficiently identify dangerously ill children so that they can be treated immediately. These tools make it easier to recognize danger signs, and support integrated approaches to reducing childhood deaths from the three ... more

Download (251)

View PDF (462)

Management of Children with Intellectual and Developmental Disability in an African Setting

Maroufou Jules Alao, Blaise Ayivi and Didier Lacombe (2012) CC

Chapter 2 in "Latest Findings in Intellectual and Developmental Disabilities Research" Edited by Üner Tan, ISBN 978-953-307-865-6, 404 pages, Publisher: InTech, Chapters published February 15, 2012 under CC BY 3.0 license | Intellectual and Developmental Disabilities presents reports on a wide rang... more

Download (637)

View PDF (1316)

National Acceleration Plan For Paediatric HIV Services: Ghana 2016 - 2020

United Nations Children’s Fund (UNICEF) (2016) C1

In 2014, GHS/NACP, with support from UNICEF and other partners, conducted a situation analysis on paediatric HIV care and treatment in Ghana. The purpose of this analysis was to identify the gaps within the current delivery of paediatric HIV care and support system and develop a road map for effecti... more

External Link

Retention and mortality outcomes from a community-supported public–private HIV treatment programme in Myanmar

Mburu, Gitau; Aung Zayar Paing; Nwe Ni Myint et al. (2016) CC

Journal of the International AIDS Society 2016, 19:20926
There is a growing interest in the potential contribution the private sector can make towards increasing access to antiretroviral therapy (ART) in low‐ and middle‐income settings. This article describes a public–private partnership ... more

Download (343)

View PDF (590)

Tuberculosis surveillance and monitoring in Europe - 2020 data
recommended

WHO Regional Office for Europe (WHOEurope) and the European Centre for Disease Prevention and Control (ECDC). (2022) C1

TB remains one of the world’s deadliest infectious diseases, second only to COVID-19, and drug-resistant TB strains are still a major concern. In the fight against TB, urgent investment is critical, especially in the context of the ongoing pandemic.

Shorter Treatment for Nonsevere Tuberculosis in African and Indian Children recommended

Selection and Use of Essential Medicines 2021 recommended

Fever Diagnostic Technology Landscape recommended

Tuberculosis surveillance and monitoring in Europe - 2020 data recommended

Shorter Treatment for Nonsevere Tuberculosis in African and Indian Children
recommended

Selection and Use of Essential Medicines 2021
recommended

Fever Diagnostic Technology Landscape
recommended

Tuberculosis surveillance and monitoring in Europe - 2020 data
recommended